Literature DB >> 8732289

Synthesis and characterization of a selective peptide antagonist of neuropeptide Y vascular postsynaptic receptors.

M J Lew1, R Murphy, J A Angus.   

Abstract

1. A cyclic dimeric nonapeptide neuropeptide Y (NPY) receptor antagonist, 1229U91, was synthesized by Fmoc chemistry and dimerised in solution. Its effects were assayed in mesenteric arteries from rats and mice, and in rat vas deferens. 2. Mesenteric arteries were cannulated and pressurised to 55 mmHg and the external diameters continuously measured. NPY, PYY, Leu31Pro34NPY and NPY(13-36) each caused concentration-related contractions with the order of potency PYY > or = Leu31Pro34NPY = NPY > NPY (13-36), consistent with the Y1 receptor subtype. 3. 1229U91 had no agonist activity in the arteries but caused a concentration-related rightward shift of NPY (mouse arteries) or Leu31Pro34NPY (rat) concentration-response curves. The antagonism was competitive with pKBS of 7.69 +/- 0.15 and 7.47 +/- 0.13 in the mouse and rat arteries, respectively. 4. Sympathetic nerves in the vas deferens were stimulated with a single electrical field pulse every 20 s and the twitch responses recorded. NPY, PYY, Leu31Pro34NPY and NPY(13-36) inhibited the twitches with the order of potency PYY > NPY > NPY(13-36) >> Leu31Pro34NPY, consistent with the Y2 receptor subtype. 5. 1229U91 inhibited the vas deferens twitch with a shallow concentration-response curve and a time-course of inhibition distinct from that of NPY. 1229U91 (30 microM) did not cause a rightward shift of the NPY concentration-response curve. 1229U91 is at least 5 orders of magnitude less potent in the vas deferens than in rat brain Y2 binding assays reported by others, suggesting that the brain and vas deferens Y2 receptors are different. 6. It is concluded that 1229U91 is a competitive antagonist of NPY Y1 vascular receptors and has additional properties that inhibit the electrically evoked twitch of the rat vas deferens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732289      PMCID: PMC1909543          DOI: 10.1111/j.1476-5381.1996.tb15352.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Benextramine: a long-lasting neuropeptide Y receptor antagonist.

Authors:  M B Doughty; S S Chu; D W Miller; K Li; R E Tessel
Journal:  Eur J Pharmacol       Date:  1990-08-21       Impact factor: 4.432

Review 2.  Neuropeptide Y and its receptor antagonists. Use of an analog mixture-screening strategy.

Authors:  K Tatemoto
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

3.  Neuropeptide Y potentiates purinergic as well as adrenergic responses of the rabbit ear artery.

Authors:  V L Saville; K I Maynard; G Burnstock
Journal:  Eur J Pharmacol       Date:  1990-02-06       Impact factor: 4.432

4.  Measurement of arteriole diameter changes by analysis of television images.

Authors:  T O Neild
Journal:  Blood Vessels       Date:  1989

5.  Vasoconstrictor threshold synergism and potentiation in the rabbit isolated thoracic aorta.

Authors:  G L Stupecky; D L Murray; R E Purdy
Journal:  J Pharmacol Exp Ther       Date:  1986-09       Impact factor: 4.030

6.  Neuropeptide Y binding and inhibition of cAMP accumulation in human neuroepithelioma cells.

Authors:  L A Lobaugh; P J Blackshear
Journal:  Am J Physiol       Date:  1990-05

7.  Selective potentiation of extracellular Ca2+-dependent contraction by neuropeptide Y in rabbit mesenteric arteries.

Authors:  M Oshita; S Kigoshi; I Muramatsu
Journal:  Gen Pharmacol       Date:  1989

8.  Endothelium-independent potentiation by neuropeptide Y of vasoconstrictor responses in isolated arteries from rat and rabbit.

Authors:  H Gustafsson; H Nilsson
Journal:  Acta Physiol Scand       Date:  1990-04

9.  A novel inositol phosphate selectively inhibits vasoconstriction evoked by the sympathetic co-transmitters neuropeptide Y (NPY) and adenosine triphosphate (ATP).

Authors:  C Wahlestedt; D J Reis; H Yoo; M Adamsson; D Andersson; L Edvinsson
Journal:  Neurosci Lett       Date:  1992-08-31       Impact factor: 3.046

10.  Enhancement by neuropeptide Y (NPY) of the dihydropyridine-sensitive component of the response to alpha 1-adrenoceptor stimulation in rat isolated mesenteric arterioles.

Authors:  R Andriantsitohaina; J C Stoclet
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

View more
  6 in total

1.  Agonist- and antagonist-induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells.

Authors:  Leng Hong Pheng; Yvan Dumont; Alain Fournier; Jean-Guy Chabot; Alain Beaudet; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

2.  Neuropeptide Y is a prejunctional inhibitor of vagal but not sympathetic inotropic responses in guinea-pig isolated left atria.

Authors:  A P Serone; J A Angus
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

3.  Heterogeneity of prejunctional NPY receptor-mediated inhibition of cardiac neurotransmission.

Authors:  A P Serone; C E Wright; J A Angus
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

4.  Neuropeptide Y regulates intracellular calcium through different signalling pathways linked to a Y(1)-receptor in rat mesenteric small arteries.

Authors:  D Prieto; C L Buus; M J Mulvany; H Nilsson
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

5.  Neuropeptide Y modulates ATP-induced increases in internal calcium via the adenylate cyclase/protein kinase A system in a human neuroblastoma cell line.

Authors:  V Soares Lemos; B Bucher; K Takeda
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

6.  Mechanisms of melatonin-induced vasoconstriction in the rat tail artery: a paradigm of weak vasoconstriction.

Authors:  M J Lew; S Flanders
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.